Huadong Medicine Company Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
18,265
- Stock Symbol
-
000963
- Investments
-
12
- Share Price
-
$6.12
- (As of Thursday Closing)
Huadong Medicine Company General Information
Description
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Contact Information
Website
www.eastchinapharm.comCorporate Office
- 468 Yan'an Road
- Floor 7, 9 and 10, Gate No. 1, Building No. 1
- Hangzhou, 310006
- China
Corporate Office
- 468 Yan'an Road
- Floor 7, 9 and 10, Gate No. 1, Building No. 1
- Hangzhou, 310006
- China
Huadong Medicine Company Stock Performance
As of 17-Jul-2025, Huadong Medicine Company’s stock price is $6.12. Its current market cap is $10.7B with 1.75B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.12 | $5.92 | $3.80 - $6.37 | $10.7B | 1.75B | 15.6M | $0.28 |
Huadong Medicine Company Financials Summary
As of 31-Mar-2025, Huadong Medicine Company has a trailing 12-month revenue of $5.86B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 8,599,764 | 8,051,984 | 10,047,937 | 11,714,795 |
| Revenue | 5,861,173 | 5,840,142 | 5,741,975 | 5,600,173 |
| EBITDA | 601,055 | 717,654 | 607,276 | 557,331 |
| Net Income | 494,701 | 489,461 | 401,259 | 371,104 |
| Total Assets | 5,430,651 | 5,188,839 | 4,727,219 | 4,521,068 |
| Total Debt | 367,250 | 373,829 | 248,170 | 323,427 |
Huadong Medicine Company Comparisons
Industry
Financing
Details
Huadong Medicine Company Competitors (18)
One of Huadong Medicine Company’s 18 competitors is Genentech, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Pfizer Manufacturing Austria | Corporation | Orth An Der Donau, Austria | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria |
Huadong Medicine Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Huadong Medicine Company Investments & Acquisitions (12)
Huadong Medicine Company’s most recent deal was a Later Stage VC with Ashvattha Therapeutics for . The deal was made on 13-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ashvattha Therapeutics | 13-Jan-2025 | Later Stage VC | Drug Discovery | ||
| Chongqing Yuyan | 14-Nov-2023 | Early Stage VC | Other Pharmaceuticals and Biotechnology | ||
| Jinannong Group | 31-May-2023 | Merger/Acquisition | Pharmaceuticals | ||
| Huaren Technology | 08-Aug-2022 | Merger/Acquisition | Pharmaceuticals | ||
| PulseCath | 17-Sep-2021 | Later Stage VC | Therapeutic Devices |
Huadong Medicine Company ESG
Risk Overview
Risk Rating
Updated July, 01, 2025
33.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 420
Rank
Percentile
Huadong Medicine Company Exits (1)
Huadong Medicine Company’s most recent exit was on 09-Oct-2020 from Qyuns. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Qyuns | 09-Oct-2020 | Completed |
|
Huadong Medicine Company Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Doer Biologics | Hangzhou, China | 2014 | |
| Huaren Technology | Wuhu, China | 2006 | |
| Jinannong Group | Nanjing, China | 1996 | |
| Hangzhou Jiuyuan Gene Engineering Co. | Hangzhou, China | 1993 | |
| Hangzhou Zhongmei Huadong Pharmaceutical. | Hangzhou, China | 1992 |
Huadong Medicine Company FAQs
-
When was Huadong Medicine Company founded?
Huadong Medicine Company was founded in 1993.
-
Where is Huadong Medicine Company headquartered?
Huadong Medicine Company is headquartered in Hangzhou, China.
-
What is the size of Huadong Medicine Company?
Huadong Medicine Company has 18,265 total employees.
-
What industry is Huadong Medicine Company in?
Huadong Medicine Company’s primary industry is Biotechnology.
-
Is Huadong Medicine Company a private or public company?
Huadong Medicine Company is a Public company.
-
What is Huadong Medicine Company’s stock symbol?
The ticker symbol for Huadong Medicine Company is 000963.
-
What is the current stock price of Huadong Medicine Company?
As of 17-Jul-2025 the stock price of Huadong Medicine Company is $6.12.
-
What is the current market cap of Huadong Medicine Company?
The current market capitalization of Huadong Medicine Company is $10.7B.
-
What is Huadong Medicine Company’s current revenue?
The trailing twelve month revenue for Huadong Medicine Company is $5.86B.
-
Who are Huadong Medicine Company’s competitors?
Genentech, Ability Pharma, Pfizer Manufacturing Austria, Pfizer Pakistan, and GlaxoSmithKline Consumer Nigeria are some of the 18 competitors of Huadong Medicine Company.
-
What is Huadong Medicine Company’s annual earnings per share (EPS)?
Huadong Medicine Company’s EPS for 12 months was $0.28.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
